[Further experiences with the Imurek treatment in multiple sclerosis].
A report is given on 82 patients suffering from multiple sclerosis (MS) who were treated over a period of up to a maximum of eight years - average treatment 4-6 years. The best results were found in patients passing through an acute episode. Among the chronic-progressive cases, 5.1 per cent of the patients showed an improvement. In 24.4 per cent of the cases the clinical picture remained unchanged. 64.1 per cent showed a deterioration. Side-effects were gastric complaints, considerable leucocyte depression, oedemas, loss of hair, strumata, increase in transaminases, recrudescence of mycosis and pyoderma. In one case a state of confusion was observed. - Special criteria for the Imurek treatment are recommended. The necessity of a closed-meshed supervision of the patients is pointed out.
D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D011292:Premedication
D001379:Azathioprine; D011241:Prednisone
Weitere Erfahrungen mit der Imurek-behandlung bei multipler Sklerose.